Non-Alcoholic Fatty Liver Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who were part of the NHANES 2017–2020 survey (a large US national health study)
- People who have been diagnosed with a liver condition called MAFLD (a type of fatty liver disease linked to metabolic health problems), based on one of the following:
- People who have type 2 diabetes, identified by: taking medication to lower blood sugar, a blood sugar marker (HbA1c) of 6.5% or higher, a fasting blood sugar level of 7.0 mmol/L (126 mg/dL) or higher, or a blood sugar reading of 11.1 mmol/L (200 mg/dL) or higher two hours after a sugar drink
- People who are overweight or obese, meaning a body mass index (BMI) of 25 or above for people of Caucasian background, or 23 or above for people of Asian background
- People with a normal or lower BMI who have at least two of the following metabolic health concerns: a larger-than-normal waist measurement, high blood pressure or blood pressure medication use, high triglycerides (a type of fat in the blood) or medication for this, low "good" cholesterol (HDL) or medication for this, blood sugar levels in the prediabetes range, a high insulin resistance score (called HOMA-IR of 2.5 or above), or a raised inflammation marker in the blood (C-reactive protein above 2 mg/L)
Who may not be able to join:
- People for whom liver ultrasound scan results are not available
- People whose full health and clinical records are incomplete
- People under 18 years of age
- People who have been diagnosed with cancer
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Tingqiu Wang, Bachelor, The Second Affiliated Hospital of Chongqing Medical University
Phone: +8617815370539
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Controlled attenuation parameter
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.